Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Fasting and Withholding Tirzepatide on Gastric Contents in T2D and Obesity
NCT07299084Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2026
- Primary completion
- Nov 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1 trial of tirzepatide in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants with Lack of Gastric Content Retention Post-Solid Test Meal at Day 171. Started Jan 2026; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT07299084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07299084.